检索结果-南通市图书馆

Comparison of two different treatment regimens’ efficacy in neovascular age-related macular degeneration in Turkish population—based on real life data-Bosphorus RWE Study Group

引用

International Journal of Ophthalmology(English edition) 2020年第1期13卷 104-111页

作者： Burak Erden Selim Bolükbasi Abdullah Ozkaya Levent Karabas Cengiz Alagoz Zeynep Alkin Ozgür Artunay Sadik Etka Bayramoglu Gokhan Demir Mehmet Demir Ali Demircan Gürkan Erdogan Mehmet Erdogan Erdem Eris Havva Kaldirim Ismail Umut Onur Ozen Ayranci Osmanbasoglu Sezin Ozdogan Erkul Mine Oztürk Irfan Perente Kübra Sarici Nihat Sayin Dilek Yasa Ihsan Yilmaz Zeynep Yilmazabdurrahmanoglu 无 Ophthalmology Clinic Okmeydani Training and Research Hospital Ophthalmology Clinic Memorial Sisli Hospital Department of Ophthalmology Kocaeli University Faculty of Medicine Ophthalmology Clinic Beyoglu Eye Training and Research Hospital Ophthalmology Clinic Kanuni Sultan Süleyman Training and Research Hospital Ophthalmology Clinic Sisli Etfal Training and Research Hospital Ophthalmology Clinic Bagcilar Training and Research Hospital Ophthalmology Clinic Bakirkoy Dr.Sadi Konuk Training and Research Hospital Ophthalmology Clinic Istanbul Training and Research Hospital1 Ophthalmology Clinic Haseki Training and Research Hospital Bosphorus Retina Study Group

AIM: To compare two different anti-vascular endothelial growth factor(anti-VEGF) treatment regimens'-a priori pro re nata(PRN) and PRN regimen following^(th)e loading phaseanatomical and functional results in neovascular agerelated macular degeneration(n AMD) patients. METHODS: Totally 544 n AMD patients followed and treated with aflibercept(n=135) and ranibizumab(n=409)at 9 different centers between 2013 and 2015 were enrolled into^(th)is retrospective multicenter study. Patients with initial best corrected visual acuity(BCVA) interval of 1.3-0.3(log MAR) and a minimum follow-up of 12 mo were included. Patients under two different regimens-a priori pro re nata(1+PRN) or 3 consecutive intravitreal injections followed by a PRN regimen(3+PRN)-were compared in BCVA at 3^(th), 6^(th) and 12^(th) months, and in central macular^(th)ickness(CMT) at 6^(th) and 12^(th) months. The total study group, intravitreal ranibizumab(IVR) and intravitreal aflibercept(IVA) groups were evaluated separately. RESULTS: The mean CMT decreased in^(th)e 1+PRN(n=101) regimen from 407 to 358 and 340 μm and in^(th)e 3+PRN(n=443) group from 398 to 318 and finally to 310 μm at months 6 and 12, respectively. Anatomically,^(th)e CMT reduction at 6^(th) month(48.5 vs 76.4;P<0.05) was statistically significant in favor of 3+PRN group. BCVA changed in 1+PRN group from 0.77 to 0.78, 0.75 and 0.75;in 3+PRN group from 0.81 to 0.69, 0.72, and 0.76 at months 3, 6, and 12, respectively. Visual gain was statistically better in 3+PRN group at 3^(th) month(-0.01 vs 0.12;P<0.001). In IVR group, CMT reduction was in greater in 3+PRN at 6^(th)(44 vs 72) and 12^(th) month(61 vs 84), but statistically insignificant. The 3+PRN group revealed statistically better visual results at 3^(th) month(-0.02 vs 0.11, P<0.05). In IVA group, although statistically insignificant, CMT reduction(61 vs 89, 6^(th) month;85 vs 97, 12^(th) month) and visual gain(0.02 vs 0.16;0.02 vs 0.14;0.05 vs 0.11) was found in favor of 3+PRN group

关键词： aflibercept neovascular age-related macular degeneration ranibizumab loading dose treatment regimen

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Weathering the storm:COVID-19 infection in patients with hematological malignancies

引用

Journal of Zhejiang University-Science B(Biomedicine & Biotechnology) 2020年第12期21卷 921-939页

作者： Lin-qin WANG Elaine TAN SU YIN Guo-qing WEI Yong-xian HU Arnon NAGLER He HUANG Bone Marrow Transplantation Center the First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou 310003China Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy Hangzhou 310058China Institute of Hematology Zhejiang UniversityHangzhou 310058China Zhejiang Laboratory for Systems&Precision Medicine Zhejiang University Medical CenterHangzhou 310058China Hematology and Bone Marrow Transplantation Division Chaim Sheba Medical CenterTel-Hashomer 52621Israel

The coronavirus disease 2019(COVID-19)is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Within a matter of months,this highly contagious novel virus has led to a global outbreak and is still spreading rapidly across *** patients with COVID-19,underlying chronic diseases and comorbidities are associated with dismal treatment *** to their immunosuppressive status,patients with hematological malignancies(HMs)are at an increased risk of infection and have a worse prognosis than patients without ***,intensive attention should be paid to this *** this review,we summarize and analyze specific clinical manifestations for patients with coexisting COVID-19 and ***,we briefly de-scribe customized management strategies and interventions for this susceptible *** review is intended to guide clinical practice.

关键词： Coronavirus disease 2019(COVID-19) Hematological malignancies Immunosuppressive status Management strategies treatment regimen

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：